Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.
about
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactionsSummary of information on human CYP enzymes: human P450 metabolism data.Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.Pharmacogenomics of proton pump inhibitors.The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjectsDifferent inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesRelative bioavailability and pharmacokinetic comparison of two different enteric formulations of omeprazole.Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.Metabolism and transport of oxazaphosphorines and the clinical implications.Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.Population pharmacokinetics of omeprazole in a random Iranian population.Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study.Phenobarbital Treatment at a Neonatal Age Results in Decreased Efficacy of Omeprazole in Adult Mice.Functional polymer-dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes.Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism.Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.Inhibition of the microsomal metabolism of 1,8-cineole in the common brushtail possum (Trichosurus vulpecula) by terpenes and other chemicals.Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.Author's reply: Hydroxylation of lansoprazole in poor metabolizers of CYP2C19.Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
P2860
Q24564971-18642C91-E4CA-4408-BB8D-A10361A965B9Q24611315-13B03062-E02E-4040-B97A-3430D1178F8AQ32103802-E0FFB328-0D48-4771-8009-D9DC4328C048Q34051253-18D5D374-A383-48CF-8FA6-16B82A66DD67Q34188511-E8804D00-9A40-4FAB-AB25-DFA62837B34EQ34429206-4B64F475-5A53-4A39-93BF-FE208A78FEB7Q34583603-7BFCD633-074C-47DE-A68E-6BCFDF6566B5Q35646205-9D4D8EB8-45DF-427C-B997-55CB4481C3BAQ35689146-005E9836-69EE-4718-92CB-FE5DB155D8FCQ35825470-A47F4093-8414-4E71-A24C-C5C4BF39D7D6Q35826075-5EB238E3-89BF-4BBD-A774-48135B845271Q35946393-4519F573-DB74-4D52-ACF1-E2E78496DF51Q36055042-EA7C8FA9-B04D-40D2-8711-70E6C3145B4FQ36055154-7F41A305-472C-47AD-88C6-35B0B4F8FDFDQ36360811-F3A16CD7-5AAD-491E-8599-9917736D6222Q36729190-59C401DE-B002-4D09-988F-B895FC5868FDQ37128495-D6C41289-C697-4EA3-8D72-2D3FB0C5A088Q37381769-231A9633-CD8B-4F8E-A6ED-608BCC87DA9CQ38556737-32A14771-5634-4A51-831E-D738513EDB71Q38773723-2F71129D-7999-4C4B-87A8-7635B6887973Q38807048-054438E8-CB73-4C42-B590-92C832D8DD0CQ40697687-3FB3CCDC-D93C-4A96-B0EC-3F0B1B899589Q41482802-8E65C5F5-C9C5-4AAD-A37A-FA63AA7F2D34Q41593466-D9A615F7-651F-4C18-A342-BD90832924DFQ42144423-5060F916-D88D-4941-A7DA-F4B01C31AD37Q42677554-95971621-DCFA-4C24-9501-33FBD140B6B4Q42868371-FD2AD2EC-2178-42AA-8B70-EDC69234385FQ43115880-C6E20B5B-B6D9-418E-B887-9D98042C348BQ43270261-BF583687-7D84-419C-A4D5-85136898C68BQ43817651-50D94607-2029-4C25-B366-B1E5DC35C985Q44149312-C45A1BBE-A21A-48F4-97C3-A2AAEC57089FQ44320406-CFC1932A-F350-4094-8DF2-7CB9CC0E34E4Q44353604-F5EA4837-0F7D-465C-94B8-D36EC9AC3BF4Q44990286-6B443403-09F7-4C23-882F-294C4B33C610Q44998075-FB9B702E-6986-430C-A5BE-82343C20D897Q45077735-6DB11957-B171-4C46-BE90-4E982D6478F7Q45117146-B725B9F4-AFF9-4F0B-9133-138AE8BCD0C9Q45264304-F790DF47-5DDF-4A17-A134-0D4B4C4483F6Q45955794-C3AD1782-F7C4-45FC-AE43-8EA1E0DF9358Q46034425-708AACD1-623E-4336-A7CF-F434743CBF29
P2860
Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Identification of human liver ...... condary omeprazole metabolism.
@ast
Identification of human liver ...... condary omeprazole metabolism.
@en
Identification of human liver ...... condary omeprazole metabolism.
@nl
type
label
Identification of human liver ...... condary omeprazole metabolism.
@ast
Identification of human liver ...... condary omeprazole metabolism.
@en
Identification of human liver ...... condary omeprazole metabolism.
@nl
prefLabel
Identification of human liver ...... condary omeprazole metabolism.
@ast
Identification of human liver ...... condary omeprazole metabolism.
@en
Identification of human liver ...... condary omeprazole metabolism.
@nl
P2093
P2860
P1476
Identification of human liver ...... condary omeprazole metabolism.
@en
P2093
Andersson T
Birkett DJ
Veronese ME
P2860
P304
P356
10.1111/J.1365-2125.1994.TB04310.X
P407
P577
1994-06-01T00:00:00Z